Aurobindo’s Q4 FY25 revenue rose by 10.6% to ₹8,382 crore while net profit stayed near ₹903 crore.
Aurobindo Pharma ended March 31, 2025 with ₹8,382 crore in consolidated sales, up from ₹7,580 crore a year earlier after Net Profit Flat. The company’s profit after tax slipped 0.5% to ₹903 crore in Q4, compared to ₹907 crore in Q4 FY24. Earnings before interest, taxes, depreciation and amortisation fell 88 basis points to 21.4% of revenue.
In the US market, Aurobindo’s formulation business brought in ₹4,072 crore, marking a 13.5% increase driven by higher volumes and new product launches . Europe sales also rose, reaching ₹2,147 crore, a 17.2% climb on steady demand and capacity additions. Growth Markets revenue declined 7.8% to ₹786 crore amid price pressures in select regions.
For the full year, Aurobindo recorded ₹31,724 crore in operations revenue, up 9.4% from ₹29,002 crore in FY24. Full-year net profit rose 9.9% to ₹3,484 crore. The US accounted for nearly 40% of annual sales at ₹14,816 crore, while Europe and Growth Markets contributed ₹8,356 crore and ₹3,180 crore respectively.
Aurobindo’s R&D spend in Q4 stood at ₹423 crore, roughly 5% of sales, as it pursued launches and ANDA filings. The firm filed nine abbreviated new drug applications and won five final approvals in the quarter.
Vice-Chairman and Managing Director K. Nithyananda Reddy said the quarter’s results reflect consistent volume-led growth and a diverse product portfolio. He noted the company aims to push European revenue toward ₹8,500 crore in the near term through capacity enhancements.
Investors cheered the numbers, sending shares up over 2% after the results, even as analysts pointed to margin pressure from higher input costs and increasing depreciation. Aurobindo ends the fiscal year positioned for steady growth in its core US and Europe markets while navigating challenges in emerging regions.
